The Role of MEG in Assessment and Diagnosis In mTBI (MEGAbIT)

November 18, 2020 updated by: University of Nottingham

MEGAbIT The Role of OPM MEG in Assessment and Diagnosis In mTBI. An Observational Study

Head injuries are responsible for 1.4 million visits to hospital each year in the United Kingdom (UK). Most patients are allowed home the same day and make a full recovery, but some will have persistent symptoms. The investigators aim to use the latest generation of imaging technology to investigate those with mild traumatic brain injury (mTBI) to better assess them.

The investigators will invite patients presenting following trauma to the Emergency Department at Queen's Medical Centre, Nottingham, UK to participate. The investigators will compare those who have a suffered an mTBI to those who have non-head traumatic injuries. The investigators will use two magnetoencephalogram (MEG) systems and ultra-high field magnetic resonance imaging (MRI) to record the functioning and structure of the brain within days of participants' injury. The investigators will test memory and thinking skills, then follow participants for six months, record the severity of participants' symptoms, and find out who does not make a full recovery.

Multimodal imaging will consist of a standard MEG device using Superconducting Quantum Interference Device (SQUID) sensors, a novel MEG device using Optically Pumped Magnetometer (OPM) sensors and seven Tesla MRI. The investigators will test whether these innovative imaging techniques are more sensitive to the acute damage that mTBI causes than routine imaging. The investigators will also test whether early imaging can reveal who is most seriously affected, identifying those who will not recover without additional support. It is currently not clear what the predominant mechanism of damage that causes these long-term problems is and the investigators hope this study will address this. The Medical Research Council is funding this work

Study Overview

Status

Unknown

Intervention / Treatment

Study Type

Observational

Enrollment (Anticipated)

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 35 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Potential participants will be identified form those attending the Emergency department of the Queen's Medical Centre, Nottingham

Description

Inclusion criteria

  • Participant is willing and able to give informed consent for participation in the study
  • Male or female, aged 18-35
  • In the Investigator's opinion, is able and willing to comply with all study requirements.
  • Willing to allow his or her General Practitioner to be notified of participation in the study
  • Two groups will be recruited:

    1. Diagnosed by the clinical ED team with mTBI (without abnormality on standard brain structural imaging, LOC ≤30mins, amnesia for ≤24hours, GCS ≥13 at all times and recovery to GCS 15 within 24hours)
    2. Diagnosed by the clinical ED team with non-head trauma, matched for age and sex with the mTBI group.

Exclusion criteria

  • Patient requiring hospitalisation for ≥24 hours at presentation
  • Any contraindication to undergo 7T MRI scan
  • Pregnancy
  • Other neurological, developmental or psychiatric disorders e.g. brain tumour, stroke, epilepsy, Alzheimer disease, schizophrenia, post-traumatic stress disorder, major depressive disorder, bipolar disorder or history of learning disability
  • Previous hospital attendance with TBI
  • Substance or alcohol abuse within six months of enrolment
  • Taking certain medications thought to alter MEG signals: opioids and synthetic opioids (excluding codeine and dihydrocodeine), anti-epileptic drugs, sedatives, neuroleptics, and hypnotics
  • Extensive metal dental hardware e.g. braces and large metal dentures (excluding fillings), implanted medical devices or other metal objects in the head, neck, or face areas that although they hold no risk to participants during a MEG recording may cause non-removable artefacts in the MEG data.
  • Participants who have participated in another research study involving an investigational product in the past 12 weeks.
  • Any other significant disease or disorder, which, in the opinion of the Investigator, may put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
mTBI cases
Those diagnosed with mild traumatic brain injury (mTBI) without abnormality on standard brain structural imaging, LOC ≤30mins, amnesia for ≤24hours, GCS ≥13 at all times and recovery to GCS 15 within 24hours)
All participants will attend the Sir Peter Mansfield Imaging Centre for a scanning session using three imaging systems (SQUID MEG, OPM MEG and 7T MRI), cognitive testing and symptom questionnaires. Remote symptom monitoring and cognitive testing at three and six months.
Acute trauma controls
Non-head trauma controls matched for age and sex with the mTBI group
All participants will attend the Sir Peter Mansfield Imaging Centre for a scanning session using three imaging systems (SQUID MEG, OPM MEG and 7T MRI), cognitive testing and symptom questionnaires. Remote symptom monitoring and cognitive testing at three and six months.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Can mTBI participants be differentiated from non-head injured controls by measuring brain wave activity?
Time Frame: Within two weeks of injury
To measure and localize abnormal resting-state slow wave activity in an mTBI population in the acute stage (< 2 weeks post injury). Voxel-wise source reconstruction of MEG resting state data using a beamforming approach will be used to generate a normative database of brain activity in the cohort of age and sex matched non-head injured trauma participants. The investigators will compare the oscillatory power in the theta and alpha frequency band between the mTBI cohort and the normative database to generate statistical maps of abnormal brain activity on a per participant basis. These will be assessed for statistically significant loci of abnormal slow wave power.
Within two weeks of injury

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Is the SQUID or OPM MEG system preferred by participants for tolerability and ease of use?
Time Frame: Within two weeks of injury
Participant preference for the SQUID or OPM MEG system will be recorded after both scanning sessions have been completed.
Within two weeks of injury

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
What novel imaging measures best differentiate mTBI participants?
Time Frame: Assessment within two weeks of injury, follow up for six months
To measure whole-brain connectivity in the resting state between regions defined via the automated anatomical labeling atlas. This will be achieved using amplitude envelope correlation between all signals originating from each region. Measures of node strength and overall connectivity will be calculated to investigate the efficiency of communication between brain regions in the participants' brains. The investigators will also measure structural connectivity using a diffusion tensor imaging (DTI) MRI sequence and structural damage using high-resolution susceptibility weighted imaging (SWI) MRI sequence. DTI will generate volumetric maps of fractional anisotropy.
Assessment within two weeks of injury, follow up for six months
Does abnormal slow wave activity on MEG arise from areas with SWI or DTI abnormalities?
Time Frame: Assessment within two weeks of injury, follow up for six months
Compare per participant theta and alpha MEG power maps generated in the primary analysis with DTI and SWI MRI scans. Using volumetric quantitative techniques compare which MRI sequence better explains the variation in MEG signal.
Assessment within two weeks of injury, follow up for six months
Does early imaging provide prognostic information?
Time Frame: Assessment within two weeks of injury, follow up for six months
Using a multivariate statistical model explore if baseline neuropsychological testing scores or memory task ability and symptom scales at six months correlate with baseline MEG and imaging abnormalities.
Assessment within two weeks of injury, follow up for six months
Is there a failure of the network responsible for attention switching in mTBI and is this correlated with objective deficits?
Time Frame: Assessment within two weeks of injury, follow up for six months
Using a visual attention MEG protocol the investigators will assess participants' ability to switch their attention to different areas of their visual field during a task. The investigators anticipate the normally observed relative reduction in alpha and increase in gamma power over the contralateral occipital lobe will be disrupted in the mTBI participants compared to controls. The investigators hypothesis that this will be linked to worse task performance and they will compare whether both failure to modulate power and task performance are correlated with objective clinical measures.
Assessment within two weeks of injury, follow up for six months
Is there a failure of the network responsible for working memory in mTBI and is this correlated with objective deficits?
Time Frame: Assessment within two weeks of injury, follow up for six months
Using an N-back working memory MEG protocol the investigators will assess participants' memory for worse task performance in the acute mTBI cohort and they will compare whether both MEG signal change and task performance are correlated with objective clinical measures.
Assessment within two weeks of injury, follow up for six months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Nikos Evangelou, MD, Clinical Neurology, Division of Clinical Neuroscience, University of Nottingham, UK

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 6, 2019

Primary Completion (Anticipated)

May 5, 2021

Study Completion (Anticipated)

November 5, 2022

Study Registration Dates

First Submitted

February 25, 2019

First Submitted That Met QC Criteria

March 5, 2019

First Posted (Actual)

March 8, 2019

Study Record Updates

Last Update Posted (Actual)

November 19, 2020

Last Update Submitted That Met QC Criteria

November 18, 2020

Last Verified

November 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Brain Injuries, Traumatic

Clinical Trials on Multimodal imaging

Subscribe